APO Research
Talk to an analyst

APO RESEARCH · REPORT

NK-1 Receptor Antagonists

Compare research editions
View pricing & licenses

Selected research

Industry Research

NK-1 Receptor Antagonists Industry Research Report 2026

28 December 2025146 pages

Choose your research edition.

Industry ResearchNK-1 Receptor Antagonists Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal NK-1 Receptor Antagonists Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal NK-1 Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NK-1 Receptor Antagonists Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal NK-1 Receptor Antagonists Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global NK-1 Receptor Antagonists market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for NK-1 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for NK-1 Receptor Antagonists is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for NK-1 Receptor Antagonists is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of NK-1 Receptor Antagonists include Dr. Reddy's Laboratories, Eugia Pharma, Fresenius Kabi, Glenmark, Helsinn Healthcare, Heron Therapeutics, Lupin, MSN and Mylan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global NK-1 Receptor Antagonists market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

NK-1 Receptor Antagonists Market by Company

Dr. Reddy's Laboratories

Eugia Pharma

Fresenius Kabi

Glenmark

Helsinn Healthcare

Heron Therapeutics

Lupin

MSN

Mylan

Steriscience

TerSera Therapeutics

Teva

Torrent Pharmaceuticals

Beijing Sihuan Pharmaceutical

Hansoh Pharma

Merck

Qilu Pharmaceutical

Sandoz

Yichang Humanwell Pharmaceutical

Chia Tai Tianqing Pharmaceutical

NK-1 Receptor Antagonists Segment by Type

Netupitant

Maropitant

Rolapitant

Fosaprepitant

Aprepitant

Other

NK-1 Receptor Antagonists Segment by Application

Chemotherapy-induced Nausea and Vomiting (CINV)

Postoperative Nausea and Vomiting (PONV)

Other

NK-1 Receptor Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK-1 Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NK-1 Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK-1 Receptor Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of NK-1 Receptor Antagonists manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of NK-1 Receptor Antagonists by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of NK-1 Receptor Antagonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global NK-1 Receptor Antagonists Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global NK-1 Receptor Antagonists Sales (K Units) of Manufacturers (2021-2026) Table 7. Global NK-1 Receptor Antagonists Sales Market Share by Manufacturers (2021-2026) Table 8. Global NK-1 Receptor Antagonists Revenue of Manufacturers (2021-2026) Table 9. Global NK-1 Receptor Antagonists Revenue Share by Manufacturers (2021-2026) Table 10. Global Market NK-1 Receptor Antagonists Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global NK-1 Receptor Antagonists Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of NK-1 Receptor Antagonists, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of NK-1 Receptor Antagonists, Product Type & Application Table 14. Global NK-1 Receptor Antagonists Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global NK-1 Receptor Antagonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Dr. Reddy's Laboratories Company Information Table 19. Dr. Reddy's Laboratories Business Overview Table 20. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolio Table 22. Dr. Reddy's Laboratories Recent Developments Table 23. Eugia Pharma Company Information Table 24. Eugia Pharma Business Overview Table 25. Eugia Pharma NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Eugia Pharma NK-1 Receptor Antagonists Product Portfolio Table 27. Eugia Pharma Recent Developments Table 28. Fresenius Kabi Company Information Table 29. Fresenius Kabi Business Overview Table 30. Fresenius Kabi NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Fresenius Kabi NK-1 Receptor Antagonists Product Portfolio Table 32. Fresenius Kabi Recent Developments Table 33. Glenmark Company Information Table 34. Glenmark Business Overview Table 35. Glenmark NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Glenmark NK-1 Receptor Antagonists Product Portfolio Table 37. Glenmark Recent Developments Table 38. Helsinn Healthcare Company Information Table 39. Helsinn Healthcare Business Overview Table 40. Helsinn Healthcare NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolio Table 42. Helsinn Healthcare Recent Developments Table 43. Heron Therapeutics Company Information Table 44. Heron Therapeutics Business Overview Table 45. Heron Therapeutics NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Heron Therapeutics NK-1 Receptor Antagonists Product Portfolio Table 47. Heron Therapeutics Recent Developments Table 48. Lupin Company Information Table 49. Lupin Business Overview Table 50. Lupin NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Lupin NK-1 Receptor Antagonists Product Portfolio Table 52. Lupin Recent Developments Table 53. MSN Company Information Table 54. MSN Business Overview Table 55. MSN NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. MSN NK-1 Receptor Antagonists Product Portfolio Table 57. MSN Recent Developments Table 58. Mylan Company Information Table 59. Mylan Business Overview Table 60. Mylan NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Mylan NK-1 Receptor Antagonists Product Portfolio Table 62. Mylan Recent Developments Table 63. Steriscience Company Information Table 64. Steriscience Business Overview Table 65. Steriscience NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Steriscience NK-1 Receptor Antagonists Product Portfolio Table 67. Steriscience Recent Developments Table 68. TerSera Therapeutics Company Information Table 69. TerSera Therapeutics Business Overview Table 70. TerSera Therapeutics NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolio Table 72. TerSera Therapeutics Recent Developments Table 73. Teva Company Information Table 74. Teva Business Overview Table 75. Teva NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Teva NK-1 Receptor Antagonists Product Portfolio Table 77. Teva Recent Developments Table 78. Torrent Pharmaceuticals Company Information Table 79. Torrent Pharmaceuticals Business Overview Table 80. Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolio Table 82. Torrent Pharmaceuticals Recent Developments Table 83. Beijing Sihuan Pharmaceutical Company Information Table 84. Beijing Sihuan Pharmaceutical Business Overview Table 85. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 87. Beijing Sihuan Pharmaceutical Recent Developments Table 88. Hansoh Pharma Company Information Table 89. Hansoh Pharma Business Overview Table 90. Hansoh Pharma NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Hansoh Pharma NK-1 Receptor Antagonists Product Portfolio Table 92. Hansoh Pharma Recent Developments Table 93. Merck Company Information Table 94. Merck Business Overview Table 95. Merck NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Merck NK-1 Receptor Antagonists Product Portfolio Table 97. Merck Recent Developments Table 98. Qilu Pharmaceutical Company Information Table 99. Qilu Pharmaceutical Business Overview Table 100. Qilu Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 102. Qilu Pharmaceutical Recent Developments Table 103. Sandoz Company Information Table 104. Sandoz Business Overview Table 105. Sandoz NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Sandoz NK-1 Receptor Antagonists Product Portfolio Table 107. Sandoz Recent Developments Table 108. Yichang Humanwell Pharmaceutical Company Information Table 109. Yichang Humanwell Pharmaceutical Business Overview Table 110. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 112. Yichang Humanwell Pharmaceutical Recent Developments Table 113. Chia Tai Tianqing Pharmaceutical Company Information Table 114. Chia Tai Tianqing Pharmaceutical Business Overview Table 115. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 117. Chia Tai Tianqing Pharmaceutical Recent Developments Table 118. Global NK-1 Receptor Antagonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 119. Global NK-1 Receptor Antagonists Sales by Region (2021-2026) & (K Units) Table 120. Global NK-1 Receptor Antagonists Sales Market Share by Region (2021-2026) Table 121. Global NK-1 Receptor Antagonists Sales by Region (2027-2032) & (K Units) Table 122. Global NK-1 Receptor Antagonists Sales Market Share by Region (2027-2032) Table 123. Global NK-1 Receptor Antagonists Revenue by Region (2021-2026) & (US$ Million) Table 124. Global NK-1 Receptor Antagonists Revenue Market Share by Region (2021-2026) Table 125. Global NK-1 Receptor Antagonists Revenue by Region (2027-2032) & (US$ Million) Table 126. Global NK-1 Receptor Antagonists Revenue Market Share by Region (2027-2032) Table 127. North America NK-1 Receptor Antagonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. North America NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units) Table 129. North America NK-1 Receptor Antagonists Sales by Country (2027-2032) & (K Units) Table 130. North America NK-1 Receptor Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 131. North America NK-1 Receptor Antagonists Revenue by Country (2027-2032) & (US$ Million) Table 132. Europe NK-1 Receptor Antagonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Europe NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units) Table 134. Europe NK-1 Receptor Antagonists Sales by Country (2027-2032) & (K Units) Table 135. Europe NK-1 Receptor Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 136. Europe NK-1 Receptor Antagonists Revenue by Country (2027-2032) & (US$ Million) Table 137. Asia Pacific NK-1 Receptor Antagonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Asia Pacific NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units) Table 139. Asia Pacific NK-1 Receptor Antagonists Sales by Country (2027-2032) & (K Units) Table 140. Asia Pacific NK-1 Receptor Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 141. Asia Pacific NK-1 Receptor Antagonists Revenue by Country (2027-2032) & (US$ Million) Table 142. South America NK-1 Receptor Antagonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. South America NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units) Table 144. South America NK-1 Receptor Antagonists Sales by Country (2027-2032) & (K Units) Table 145. South America NK-1 Receptor Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 146. South America NK-1 Receptor Antagonists Revenue by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa NK-1 Receptor Antagonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Middle East and Africa NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units) Table 149. Middle East and Africa NK-1 Receptor Antagonists Sales by Country (2027-2032) & (K Units) Table 150. Middle East and Africa NK-1 Receptor Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 151. Middle East and Africa NK-1 Receptor Antagonists Revenue by Country (2027-2032) & (US$ Million) Table 152. Global NK-1 Receptor Antagonists Sales by Type (2021-2026) & (K Units) Table 153. Global NK-1 Receptor Antagonists Sales by Type (2027-2032) & (K Units) Table 154. Global NK-1 Receptor Antagonists Sales Market Share by Type (2021-2026) Table 155. Global NK-1 Receptor Antagonists Sales Market Share by Type (2027-2032) Table 156. Global NK-1 Receptor Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 157. Global NK-1 Receptor Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 158. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2021-2026) Table 159. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2027-2032) Table 160. Global NK-1 Receptor Antagonists Price by Type (2021-2026) & (US$/Unit) Table 161. Global NK-1 Receptor Antagonists Price by Type (2027-2032) & (US$/Unit) Table 162. Global NK-1 Receptor Antagonists Sales by Application (2021-2026) & (K Units) Table 163. Global NK-1 Receptor Antagonists Sales by Application (2027-2032) & (K Units) Table 164. Global NK-1 Receptor Antagonists Sales Market Share by Application (2021-2026) Table 165. Global NK-1 Receptor Antagonists Sales Market Share by Application (2027-2032) Table 166. Global NK-1 Receptor Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 167. Global NK-1 Receptor Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 168. Global NK-1 Receptor Antagonists Revenue Market Share by Application (2021-2026) Table 169. Global NK-1 Receptor Antagonists Revenue Market Share by Application (2027-2032) Table 170. Global NK-1 Receptor Antagonists Price by Application (2021-2026) & (US$/Unit) Table 171. Global NK-1 Receptor Antagonists Price by Application (2027-2032) & (US$/Unit) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. NK-1 Receptor Antagonists Distributors List Table 175. NK-1 Receptor Antagonists Customers List Table 176. NK-1 Receptor Antagonists Industry Trends Table 177. NK-1 Receptor Antagonists Industry Drivers Table 178. NK-1 Receptor Antagonists Industry Restraints Table 179. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. NK-1 Receptor Antagonists Product Image Figure 5. Global NK-1 Receptor Antagonists Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global NK-1 Receptor Antagonists Market Size (2021-2032) & (US$ Million) Figure 7. Global NK-1 Receptor Antagonists Sales (2021-2032) & (K Units) Figure 8. Global NK-1 Receptor Antagonists Average Price (US$/Unit) & (2021-2032) Figure 9. Netupitant Product Image Figure 10. Maropitant Product Image Figure 11. Rolapitant Product Image Figure 12. Fosaprepitant Product Image Figure 13. Aprepitant Product Image Figure 14. Other Product Image Figure 15. Chemotherapy-induced Nausea and Vomiting (CINV) Product Image Figure 16. Postoperative Nausea and Vomiting (PONV) Product Image Figure 17. Other Product Image Figure 18. Global NK-1 Receptor Antagonists Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of NK-1 Receptor Antagonists, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 NK-1 Receptor Antagonists Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global NK-1 Receptor Antagonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global NK-1 Receptor Antagonists Sales by Region in 2025 Figure 24. Global NK-1 Receptor Antagonists Revenue by Region in 2025 Figure 25. North America NK-1 Receptor Antagonists Market Size by Country in 2025 Figure 26. North America NK-1 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 27. North America NK-1 Receptor Antagonists Revenue Market Share by Country (2021-2032) Figure 28. United States NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Mexico NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe NK-1 Receptor Antagonists Market Size by Country in 2025 Figure 32. Europe NK-1 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 33. Europe NK-1 Receptor Antagonists Revenue Market Share by Country (2021-2032) Figure 34. Germany NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Russia NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Spain NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Netherlands NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Switzerland NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Sweden NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Poland NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Asia Pacific NK-1 Receptor Antagonists Market Size by Country in 2025 Figure 45. Asia Pacific NK-1 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 46. Asia Pacific NK-1 Receptor Antagonists Revenue Market Share by Country (2021-2032) Figure 47. China NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Japan NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South Korea NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. India NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Australia NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Taiwan NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. South America NK-1 Receptor Antagonists Market Size by Country in 2025 Figure 56. South America NK-1 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 57. South America NK-1 Receptor Antagonists Revenue Market Share by Country (2021-2032) Figure 58. Brazil NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Argentina NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Chile NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa NK-1 Receptor Antagonists Market Size by Country in 2025 Figure 62. Middle East and Africa NK-1 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa NK-1 Receptor Antagonists Revenue Market Share by Country (2021-2032) Figure 64. Egypt NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries NK-1 Receptor Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global NK-1 Receptor Antagonists Sales Market Share by Type (2021-2032) Figure 70. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2021-2032) Figure 71. Global NK-1 Receptor Antagonists Price (US$/Unit) by Type (2021-2032) Figure 72. Global NK-1 Receptor Antagonists Sales Market Share by Application (2021-2032) Figure 73. Global NK-1 Receptor Antagonists Revenue Market Share by Application (2021-2032) Figure 74. Global NK-1 Receptor Antagonists Price (US$/Unit) by Application (2021-2032) Figure 75. NK-1 Receptor Antagonists Value Chain Figure 76. NK-1 Receptor Antagonists Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. NK-1 Receptor Antagonists Industry Opportunities and Challenges

Scope & coverage.

Types
  • Netupitant
  • Maropitant
  • Rolapitant
  • Fosaprepitant
  • Aprepitant
  • Other
Applications
  • Chemotherapy-induced Nausea and Vomiting (CINV)
  • Postoperative Nausea and Vomiting (PONV)
  • Other
Companies covered
  • Dr. Reddy's Laboratories
  • Eugia Pharma
  • Fresenius Kabi
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • Lupin
  • MSN
  • Mylan
  • Steriscience
  • TerSera Therapeutics
  • Teva
  • Torrent Pharmaceuticals
  • Beijing Sihuan Pharmaceutical
  • Hansoh Pharma
  • Merck
  • Qilu Pharmaceutical
  • Sandoz
  • Yichang Humanwell Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global NK-1 Receptor Antagonists Market Size (2021-2032)
  4. 2.2.2 Global NK-1 Receptor Antagonists Sales (2021-2032)
  5. 2.2.3 Global NK-1 Receptor Antagonists Market Average Price (2021-2032)
  6. 2.3 NK-1 Receptor Antagonists by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Netupitant
  9. 2.3.3 Maropitant
  10. 2.3.4 Rolapitant
  11. 2.3.5 Fosaprepitant
  12. 2.3.6 Aprepitant
  13. 2.3.7 Other
  14. 2.4 NK-1 Receptor Antagonists by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Chemotherapy-induced Nausea and Vomiting (CINV)
  17. 2.4.3 Postoperative Nausea and Vomiting (PONV)
  18. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global NK-1 Receptor Antagonists Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global NK-1 Receptor Antagonists Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global NK-1 Receptor Antagonists Revenue of Manufacturers (2021-2026)
  4. 3.4 Global NK-1 Receptor Antagonists Average Price by Manufacturers (2021-2026)
  5. 3.5 Global NK-1 Receptor Antagonists Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of NK-1 Receptor Antagonists, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of NK-1 Receptor Antagonists, Product Type & Application
  8. 3.8 Global Manufacturers of NK-1 Receptor Antagonists, Established Date
  9. 3.9 Global NK-1 Receptor Antagonists Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Dr. Reddy's Laboratories
  2. 4.1.1 Dr. Reddy's Laboratories Company Information
  3. 4.1.2 Dr. Reddy's Laboratories Business Overview
  4. 4.1.3 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolio
  6. 4.1.5 Dr. Reddy's Laboratories Recent Developments
  7. 4.2 Eugia Pharma
  8. 4.2.1 Eugia Pharma Company Information
  9. 4.2.2 Eugia Pharma Business Overview
  10. 4.2.3 Eugia Pharma NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Eugia Pharma NK-1 Receptor Antagonists Product Portfolio
  12. 4.2.5 Eugia Pharma Recent Developments
  13. 4.3 Fresenius Kabi
  14. 4.3.1 Fresenius Kabi Company Information
  15. 4.3.2 Fresenius Kabi Business Overview
  16. 4.3.3 Fresenius Kabi NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Fresenius Kabi NK-1 Receptor Antagonists Product Portfolio
  18. 4.3.5 Fresenius Kabi Recent Developments
  19. 4.4 Glenmark
  20. 4.4.1 Glenmark Company Information
  21. 4.4.2 Glenmark Business Overview
  22. 4.4.3 Glenmark NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Glenmark NK-1 Receptor Antagonists Product Portfolio
  24. 4.4.5 Glenmark Recent Developments
  25. 4.5 Helsinn Healthcare
  26. 4.5.1 Helsinn Healthcare Company Information
  27. 4.5.2 Helsinn Healthcare Business Overview
  28. 4.5.3 Helsinn Healthcare NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolio
  30. 4.5.5 Helsinn Healthcare Recent Developments
  31. 4.6 Heron Therapeutics
  32. 4.6.1 Heron Therapeutics Company Information
  33. 4.6.2 Heron Therapeutics Business Overview
  34. 4.6.3 Heron Therapeutics NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Heron Therapeutics NK-1 Receptor Antagonists Product Portfolio
  36. 4.6.5 Heron Therapeutics Recent Developments
  37. 4.7 Lupin
  38. 4.7.1 Lupin Company Information
  39. 4.7.2 Lupin Business Overview
  40. 4.7.3 Lupin NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Lupin NK-1 Receptor Antagonists Product Portfolio
  42. 4.7.5 Lupin Recent Developments
  43. 4.8 MSN
  44. 4.8.1 MSN Company Information
  45. 4.8.2 MSN Business Overview
  46. 4.8.3 MSN NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 MSN NK-1 Receptor Antagonists Product Portfolio
  48. 4.8.5 MSN Recent Developments
  49. 4.9 Mylan
  50. 4.9.1 Mylan Company Information
  51. 4.9.2 Mylan Business Overview
  52. 4.9.3 Mylan NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Mylan NK-1 Receptor Antagonists Product Portfolio
  54. 4.9.5 Mylan Recent Developments
  55. 4.10 Steriscience
  56. 4.10.1 Steriscience Company Information
  57. 4.10.2 Steriscience Business Overview
  58. 4.10.3 Steriscience NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Steriscience NK-1 Receptor Antagonists Product Portfolio
  60. 4.10.5 Steriscience Recent Developments
  61. 4.11 TerSera Therapeutics
  62. 4.11.1 TerSera Therapeutics Company Information
  63. 4.11.2 TerSera Therapeutics Business Overview
  64. 4.11.3 TerSera Therapeutics NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolio
  66. 4.11.5 TerSera Therapeutics Recent Developments
  67. 4.12 Teva
  68. 4.12.1 Teva Company Information
  69. 4.12.2 Teva Business Overview
  70. 4.12.3 Teva NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Teva NK-1 Receptor Antagonists Product Portfolio
  72. 4.12.5 Teva Recent Developments
  73. 4.13 Torrent Pharmaceuticals
  74. 4.13.1 Torrent Pharmaceuticals Company Information
  75. 4.13.2 Torrent Pharmaceuticals Business Overview
  76. 4.13.3 Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolio
  78. 4.13.5 Torrent Pharmaceuticals Recent Developments
  79. 4.14 Beijing Sihuan Pharmaceutical
  80. 4.14.1 Beijing Sihuan Pharmaceutical Company Information
  81. 4.14.2 Beijing Sihuan Pharmaceutical Business Overview
  82. 4.14.3 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  84. 4.14.5 Beijing Sihuan Pharmaceutical Recent Developments
  85. 4.15 Hansoh Pharma
  86. 4.15.1 Hansoh Pharma Company Information
  87. 4.15.2 Hansoh Pharma Business Overview
  88. 4.15.3 Hansoh Pharma NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Hansoh Pharma NK-1 Receptor Antagonists Product Portfolio
  90. 4.15.5 Hansoh Pharma Recent Developments
  91. 4.16 Merck
  92. 4.16.1 Merck Company Information
  93. 4.16.2 Merck Business Overview
  94. 4.16.3 Merck NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Merck NK-1 Receptor Antagonists Product Portfolio
  96. 4.16.5 Merck Recent Developments
  97. 4.17 Qilu Pharmaceutical
  98. 4.17.1 Qilu Pharmaceutical Company Information
  99. 4.17.2 Qilu Pharmaceutical Business Overview
  100. 4.17.3 Qilu Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  102. 4.17.5 Qilu Pharmaceutical Recent Developments
  103. 4.18 Sandoz
  104. 4.18.1 Sandoz Company Information
  105. 4.18.2 Sandoz Business Overview
  106. 4.18.3 Sandoz NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Sandoz NK-1 Receptor Antagonists Product Portfolio
  108. 4.18.5 Sandoz Recent Developments
  109. 4.19 Yichang Humanwell Pharmaceutical
  110. 4.19.1 Yichang Humanwell Pharmaceutical Company Information
  111. 4.19.2 Yichang Humanwell Pharmaceutical Business Overview
  112. 4.19.3 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  114. 4.19.5 Yichang Humanwell Pharmaceutical Recent Developments
  115. 4.20 Chia Tai Tianqing Pharmaceutical
  116. 4.20.1 Chia Tai Tianqing Pharmaceutical Company Information
  117. 4.20.2 Chia Tai Tianqing Pharmaceutical Business Overview
  118. 4.20.3 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  120. 4.20.5 Chia Tai Tianqing Pharmaceutical Recent Developments
5 Global NK-1 Receptor Antagonists Market Scenario by Region
  1. 5.1 Global NK-1 Receptor Antagonists Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global NK-1 Receptor Antagonists Sales by Region: 2021-2032
  3. 5.2.1 Global NK-1 Receptor Antagonists Sales by Region: 2021-2026
  4. 5.2.2 Global NK-1 Receptor Antagonists Sales by Region: 2027-2032
  5. 5.3 Global NK-1 Receptor Antagonists Revenue by Region: 2021-2032
  6. 5.3.1 Global NK-1 Receptor Antagonists Revenue by Region: 2021-2026
  7. 5.3.2 Global NK-1 Receptor Antagonists Revenue by Region: 2027-2032
  8. 5.4 North America NK-1 Receptor Antagonists Market Facts & Figures by Country
  9. 5.4.1 North America NK-1 Receptor Antagonists Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America NK-1 Receptor Antagonists Sales by Country (2021-2032)
  11. 5.4.3 North America NK-1 Receptor Antagonists Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe NK-1 Receptor Antagonists Market Facts & Figures by Country
  16. 5.5.1 Europe NK-1 Receptor Antagonists Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe NK-1 Receptor Antagonists Sales by Country (2021-2032)
  18. 5.5.3 Europe NK-1 Receptor Antagonists Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific NK-1 Receptor Antagonists Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific NK-1 Receptor Antagonists Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific NK-1 Receptor Antagonists Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific NK-1 Receptor Antagonists Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America NK-1 Receptor Antagonists Market Facts & Figures by Country
  41. 5.7.1 South America NK-1 Receptor Antagonists Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America NK-1 Receptor Antagonists Sales by Country (2021-2032)
  43. 5.7.3 South America NK-1 Receptor Antagonists Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa NK-1 Receptor Antagonists Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa NK-1 Receptor Antagonists Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa NK-1 Receptor Antagonists Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa NK-1 Receptor Antagonists Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global NK-1 Receptor Antagonists Sales by Type (2021-2032)
  2. 6.1.1 Global NK-1 Receptor Antagonists Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global NK-1 Receptor Antagonists Sales Market Share by Type (2021-2032)
  4. 6.2 Global NK-1 Receptor Antagonists Revenue by Type (2021-2032)
  5. 6.2.1 Global NK-1 Receptor Antagonists Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global NK-1 Receptor Antagonists Revenue Market Share by Type (2021-2032)
  7. 6.3 Global NK-1 Receptor Antagonists Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global NK-1 Receptor Antagonists Sales by Application (2021-2032)
  2. 7.1.1 Global NK-1 Receptor Antagonists Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global NK-1 Receptor Antagonists Sales Market Share by Application (2021-2032)
  4. 7.2 Global NK-1 Receptor Antagonists Revenue by Application (2021-2032)
  5. 7.2.1 Global NK-1 Receptor Antagonists Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global NK-1 Receptor Antagonists Revenue Market Share by Application (2021-2032)
  7. 7.3 Global NK-1 Receptor Antagonists Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 NK-1 Receptor Antagonists Value Chain Analysis
  2. 8.1.1 NK-1 Receptor Antagonists Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 NK-1 Receptor Antagonists Production Mode & Process
  5. 8.2 NK-1 Receptor Antagonists Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 NK-1 Receptor Antagonists Distributors
  8. 8.2.3 NK-1 Receptor Antagonists Customers
9 Global NK-1 Receptor Antagonists Analyzing Market Dynamics
  1. 9.1 NK-1 Receptor Antagonists Industry Trends
  2. 9.2 NK-1 Receptor Antagonists Industry Drivers
  3. 9.3 NK-1 Receptor Antagonists Industry Opportunities and Challenges
  4. 9.4 NK-1 Receptor Antagonists Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst